BIOLASE, Inc.
BIOLQ
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -7.44% | -9.28% | 0.13% | 1.45% | 6.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.44% | -9.28% | 0.13% | 1.45% | 6.21% |
| Cost of Revenue | -8.36% | -12.56% | -6.25% | -0.34% | 11.25% |
| Gross Profit | -5.63% | -1.81% | 15.19% | 5.12% | -2.46% |
| SG&A Expenses | -22.75% | -21.71% | -16.40% | -15.68% | -3.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.15% | -17.67% | -12.22% | -9.08% | 2.27% |
| Operating Income | 36.50% | 34.55% | 35.02% | 29.22% | 5.88% |
| Income Before Tax | 36.08% | 33.62% | 28.35% | 27.79% | -4.49% |
| Income Tax Expenses | -72.93% | -61.39% | -46.24% | -70.64% | 40.00% |
| Earnings from Continuing Operations | 36.28% | 33.72% | 28.41% | 27.95% | -4.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.28% | 33.72% | 28.41% | 27.95% | -4.63% |
| EBIT | 36.50% | 34.55% | 35.02% | 29.22% | 5.88% |
| EBITDA | 42.73% | 40.29% | 46.47% | 39.06% | 14.02% |
| EPS Basic | 95.79% | 93.66% | 87.45% | 83.93% | 49.52% |
| Normalized Basic EPS | 98.61% | 97.73% | 95.76% | 90.96% | 58.02% |
| EPS Diluted | 95.79% | 93.66% | 87.45% | 83.93% | 49.52% |
| Normalized Diluted EPS | 98.61% | 97.73% | 95.76% | 90.96% | 58.02% |
| Average Basic Shares Outstanding | 4,276.22% | 5,666.30% | 4,632.36% | 1,719.54% | 694.04% |
| Average Diluted Shares Outstanding | 4,276.22% | 5,666.30% | 4,632.36% | 1,719.54% | 694.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |